Figure 6.—

Expression of fc106ΔQ²⁰–E⁴⁷³ in wild-type and dec-1⁴ mutant egg chambers. (A) A schematic of fc106 with its major regions indicated above. The lines below the schematic indicate the regions that are present in the fc106ΔV²⁸⁸–E⁴⁷³ (*D288–473) and fc106ΔQ²⁰–E⁴⁷³ (*D20–473) transgenes. The abbreviated nomenclature used in B and C is shown to the right. (B) Developmental Western blot of SDS-soluble proteins from wild-type (w/w) egg chambers in the absence (−) or presence of mutant (*D1 or *D2) fc106 cDNA transgenes. Egg chamber stages are indicated at the bottom of each set. The positions of fc106^V, s80^V, and s60^V from the endogenous wild-type dec-1 gene as well as the fc106ΔV²⁸⁸–E⁴⁷³ proprotein (fc106D1) are indicated to the left; the asterisk denotes the s60-like product produced by the fc106ΔQ²⁰–E⁴⁷³ (*D2) transgene. The mobility of this gene product is indistinguishable from that of the s60-like cleavage product of fc106ΔV²⁸⁸–E⁴⁷³ (*D1) (e.g., compare *D1 and *D2, stage 12). The blot was incubated with the Cfc106 antibody. (C) Expression of the full-length fc106 (*fc106) and *D2 transgenes in dec-1⁴ egg chambers. SDS-soluble egg chamber proteins were resolved using a mini-protean electrophoresis cell system. The positions of *fc106 and *D2 transgene products (fc106, s80, and s60 and s60^D2, respectively) are indicated against the background of unmarked dec-1⁴ derivatives. The egg chamber stages are shown at the bottom; the blot was incubated with the Cfc106 antiserum.